The impact of health insurance coverage on pediatric diabetes management

被引:10
作者
Wintergerst, Kupper A. [1 ]
Hinkle, Krystal M. [1 ]
Barnes, Christopher N. [2 ]
Omoruyi, Adetokunbo O. [1 ]
Foster, Michael B. [1 ]
机构
[1] Univ Louisville, Sch Med, Div Endocrinol, Dept Pediat, Louisville, KY 40202 USA
[2] Univ Louisville, Sch Publ Hlth & Informat Sci, Dept Bioinformat & Biostast, Louisville, KY 40202 USA
关键词
Insurance; Insulin; Diabetes type 1; CHILDREN; COMPLICATIONS; TYPE-1; CARE; NEPHROPATHY; FLEXPEN(R); PREFERENCE; MELLITUS; DELIVERY; QUALITY;
D O I
10.1016/j.diabres.2010.06.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Alms To examine the association between health insurance coverage, insulin management plans, and their impact on diabetes control in a pediatric type 1 diabetes mellitus clinic population Methods Retrospective cohort design drawn from the medical records of the Pediatric Endocrinology Clinic at the University of Louisville, Kentucky Results Out of 701 patients, 223 had public insurance, and 478 had private insurance 77% of publically insured used two or three injections per day vs 40% private Conversely, 58% of privately insured used a multiple daily injection (MDI) plan or insulin pump (vs. 21%) 84% of MDI patients had private insurance with 93% using insulin pens compared with 38% of publically insured. Mean HbA1c was 8 6% for privately insured vs 9 8% public, p < 0 0001 Privately insured MDI and pump patients had the lowest HbA1cs Conclusions Insurance type had a significant effect on the insulin management plan used and was the most significant factor in overall diabetes control. Limitations on insulin pen use and number of glucose test strips may play a role in the decreased use of MDI/insulin pumps by publicly insured patients. Addressing factors related to insurance type, including availability of resources, could substantially improve diabetes control in those with public insurance (C) 2010 Elsevier Ireland Ltd. All rights reserved
引用
收藏
页码:40 / 44
页数:5
相关论文
共 21 条
  • [1] [Anonymous], 2008, NAT DIAB FACT SHEET
  • [2] Diabetic nephropathy in children and adolescents
    Bogdanovic, Radovan
    [J]. PEDIATRIC NEPHROLOGY, 2008, 23 (04) : 507 - 525
  • [3] Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe
    Graff, MR
    McClanahan, MA
    [J]. CLINICAL THERAPEUTICS, 1998, 20 (03) : 486 - 496
  • [4] Predictors of control of diabetes: Monitoring may be the key
    Haller, MJ
    Stalvey, MS
    Silverstein, JH
    [J]. JOURNAL OF PEDIATRICS, 2004, 144 (05) : 660 - 661
  • [5] FlexPen®:: Addressing issues of confidence and convenience in insulin delivery
    Korytkowski, M
    Niskanen, L
    Asakura, T
    [J]. CLINICAL THERAPEUTICS, 2005, 27 : S89 - S100
  • [6] A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus
    Korytkowski, M
    Bell, D
    Jacobsen, C
    Suwannasari, R
    [J]. CLINICAL THERAPEUTICS, 2003, 25 (11) : 2836 - 2848
  • [7] Inflammation and Progressive Nephropathy in Type 1 Diabetes in the Diabetes Control and Complications Trial
    Lin, Julie
    Glynn, Robert J.
    Rifai, Nader
    Manson, JoAnn E.
    Ridker, Paul M.
    Nathan, David M.
    Schaumberg, Debra A.
    [J]. DIABETES CARE, 2008, 31 (12) : 2338 - 2343
  • [8] Moore DJ, 2009, VASC HEALTH RISK MAN, V5, P1015
  • [9] Nathan DM, 2009, ARCH INTERN MED, V169, P1307, DOI 10.1001/archinternmed.2009.193
  • [10] Nathan DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1707, DOI 10.1001/archopht.126.12.1707